SAN JOSE, Calif., May 29, 2012 /PRNewswire/ -- Ariosa Diagnostics, Inc., a molecular diagnostics company, today announced it will be presenting two studies and also exhibiting as a meeting sponsor at the upcoming ISPD 16th International Conference on Prenatal Diagnosis and Therapy in Miami Beach, Fla.
The first study will be a poster presentation titled, "Analysis of Maternal Age, Gestational Age and Aneuploidy on Fraction of Fetal Cell Free DNA." The study examines how maternal age, gestational age and trisomy status affects the fetal fraction of cell free DNA. The abstract, #P1-64, will be presented on June 4, 12:15-1:15pm EDT, by Craig Struble, PhD, director of bioinformatics at Ariosa Diagnostics.
The second study will be an oral presentation titled, "Clinical Evaluation of a Directed cfDNA Analysis Method for Non-Invasive Prenatal Fetal Trisomy Detection." The abstract will be presented on June 5, between 8:30-10:30am EDT, by Ken Song, MD, chief executive officer at Ariosa Diagnostics.
Ariosa Diagnostics developed the Harmony™ Prenatal Test, which will be broadly available through a partnership with LabCorp and Integrated Genetics. The Harmony Prenatal Test is performed using a simple maternal blood draw and detects fetal trisomy via analysis of cell-free DNA.
About Ariosa Diagnostics
Ariosa Diagnostics, Inc., is a molecular diagnostics company committed to providing safe, highly accurate and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. Ariosa's simple blood test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.
The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com.
SOURCE Ariosa Diagnostics, Inc.